Prospective Evaluation of Amino Acid Profiles and Physical Function Following Tofogliflozin Initiation in Adults With Type 2 Diabetes ― The TOFLEX Study Protocol ―
Authors:
Open Access
- 12 November 2026
- journal article
- Published by Japanese Circulation Society in Circulation Reports
- p. CR-26-0283
Abstract
Background: Type 2 diabetes mellitus (T2DM) is associated with cardiometabolic dysfunction and progressive impairment of skeletal muscle health. Sodium–glucose cotransporter 2 inhibitors (SGLT2I) improve cardiovascular and renal outcomes, but their effects on amino acid metabolism, skeletal muscle composition, and physical function remain unclear. β-aminoisobutyric acid (BAIBA), a muscle-related amino acid, may link metabolic regulation with muscle health.Methods and Results: The TOFLEX study is a single-center, single-arm, prospective observational study evaluating longitudinal changes after initiation of tofogliflozin in adults with T2DM. Participants aged ≥18 years who are scheduled to start tofogliflozin in routine clinical care will be followed for 48 weeks. The primary outcome is the change in circulating amino acid concentrations, with particular attention to BAIBA. Secondary outcomes include changes in urinary amino acid profiles, physical function assessed by the Short Physical Performance Battery and handgrip strength, skeletal muscle mass assessed by dual-energy X-ray absorptiometry and bioelectrical impedance analysis, intramuscular fat infiltration assessed by magnetic resonance imaging and/or spectroscopy, and cardiometabolic parameters.Conclusions: TOFLEX will provide prospective data on amino acid remodeling after SGLT2i initiation and explore its relationship with skeletal muscle composition and physical function in adults with T2DM.Keywords
This publication has 16 references indexed in Scilit:
- Altered Plasma Urea Cycle Metabolites Are Independently Associated With Frailty in Patients With Heart FailureCirculation Journal, 2026
- Metabolic Communication by SGLT2 InhibitionCirculation, 2024
- SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysisScientific Reports, 2023
- Circulating level of β-aminoisobutyric acid (BAIBA), a novel myokine-like molecule, is inversely associated with fat mass in patients with heart failureHeart and Vessels, 2023
- Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial ( EMPA‐ELDERLY )Diabetes, Obesity and Metabolism, 2023
- Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitorsCardiovascular Diabetology, 2022
- Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy HypothesisCirculation, 2022
- Global aetiology and epidemiology of type 2 diabetes mellitus and its complicationsNature Reviews Endocrinology, 2017
- Frailty, Sarcopenia and DiabetesJournal of the American Medical Directors Association, 2014
- β-Aminoisobutyric Acid Induces Browning of White Fat and Hepatic β-Oxidation and Is Inversely Correlated with Cardiometabolic Risk FactorsCell Metabolism, 2014